Shareholders' Inquiry Transfer Plan
Filed with SSE · · 4 pages · Chinese
Kexing Biopharm Co., Ltd. on 6ix
Earlier from Kexing Biopharm
- Announcement on Cancellation of Special Settlement Accounts for Some Raised Fund Financial Products
- Announcement on Convening the Q3 2025 Performance Briefing
- Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
- Report for Q3 2025
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
Later from Kexing Biopharm
- Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
- Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer Multiple
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Ophthalmic Preparation GB10 Injection
- Announcement on Renewing Engagement of Accounting Firm
- Announcement on Estimated Amount of Daily Related Transactions in 2026
Follow Kexing Biopharm into a list and get an email when it puts out news.
Follow Kexing Biopharm